taVNS for FRNS in Children
Eligible age
3–17 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.
Sponsor: Northwell Health
You may qualify if…
- ✓ FRNS
- ✓ Age 3-17 years
- ✓ Glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m2
- ✓ Minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) diagnosis (clinical diagnosis or per biopsy)
- ✓ Steroid sensitive nephrotic syndrome (prior history of remission within 4 weeks of steroid therapy)
- ✓ In remission at time of enrollment (remission defined as UPC \<0.2 or negative dipstick for 3 consecutive days)
- ✓ Informed consent from the parent or guardian and assent from a minor of ≥ 7. years
You may not qualify if…
- ✕ Secondary forms of nephrotic syndrome
- ✕ SRNS
- ✕ Steroid dependent nephrotic syndrome (relapse within 14 days of stopping steroids or relapse while on steroids)
- ✕ Exposure to steroids within 14 days of enrollment
- ✕ Receiving any standing immunosuppression (previous exposure \> 2 months allowed and/or B cell repletion)
- ✕ Any known inflammatory condition (e.g. systemic lupus erythematosis)
- ✕ History of cardiac disease (arrhythmias, structural/functional abnormalities)
- ✕ Implantable electronic devices
Where it's recruiting
New Hyde Park
Philadelphia
Source: ClinicalTrials.gov · NCT05588063 · last updated 2026-04-15